VELA Investment Management’s Denali Therapeutics DNLI Stock Holding History

VELA Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-27,771	Closed	-$378K	–	167
2025 Q1	$378K	Buy	27,771 +12,136	+78%	+$233K	0.12%	139
2024 Q4	$319K	Hold	15,635	–	–	0.09%	149
2024 Q3	$455K	Buy	+15,635	New	+$388K	0.14%	139
2024 Q1	–	Sell	-26,145	Closed	-$561K	–	165
2023 Q4	$561K	Buy	26,145 +6,246	+31%	+$124K	0.21%	125
2023 Q3	$411K	Sell	19,899 -773	-4%	-$19.6K	0.18%	117
2023 Q2	$610K	Hold	20,672	–	–	0.28%	101
2023 Q1	$476K	Buy	20,672 +6,926	+50%	+$191K	0.22%	116
2022 Q4	$382K	Buy	13,746 +4,905	+55%	+$146K	0.19%	119
2022 Q3	$271K	Buy	+8,841	New	+$287K	0.15%	129

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

VELA Investment Management's DNLI Position: Q2 2025 in Review

VELA Investment Management sold out of Denali Therapeutics (DNLI) in Q2 2025, closing a stake of 27,771 shares — an estimated $378K sold.

VELA Investment Management first reported a position in DNLI in Q3 2022 and held it in 9 quarters. The position peaked at $610K in Q2 2023. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

VELA Investment Management reported no remaining Denali Therapeutics position as of Q2 2025 after selling out during the quarter.
VELA Investment Management sold 27,771 Denali Therapeutics shares in Q2 2025, an estimated $378K.
VELA Investment Management first reported a position in Denali Therapeutics in Q3 2022 and held it in 9 quarters.
VELA Investment Management's Denali Therapeutics position peaked at $610K in Q2 2023.
230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on VELA Investment Management's 13F filing for Q2 2025, filed 29 Jul 2025.